Steven Ringquist

Title: Innovations of Steven Ringquist

Introduction

Steven Ringquist is a notable inventor based in Lyons, Colorado. He has made significant contributions to the field of nucleic acid research, holding a total of seven patents. His work focuses on developing methods to obtain nucleic acid ligands that can photocrosslink to target molecules associated with various disease states.

Latest Patents

One of his latest patents is titled "Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands." This patent outlines methods for obtaining nucleic acid ligands that can photocrosslink to target molecules associated with disease states. The methods presented are variations on the photoSELEX techniques, which involve contacting a candidate mixture of photocrosslinkable nucleic acids with biological substances from sources associated with disease states. The resulting nucleic acid-target molecule complexes are then irradiated to form crosslinked complexes, which are subsequently partitioned from the candidate mixture. This innovative approach allows for the retention of nucleic acid ligands that specifically bind to target molecules. Another method described involves using enriched candidate mixtures to further refine the selection process, ensuring that only nucleic acids with high affinity for disease-associated molecules are retained.

Career Highlights

Throughout his career, Steven Ringquist has worked with several prominent companies, including Nexstar Pharmaceuticals, Inc. and Somalogic, Incorporated. His experience in these organizations has contributed to his expertise in the field of nucleic acid research and innovation.

Collaborations

Steven has collaborated with notable individuals in his field, including Larry M. Gold and Michael Willis. These collaborations have likely enhanced his research and development efforts, leading to advancements in nucleic acid technologies.

Conclusion

Steven Ringquist's innovative work in nucleic acid research has led to significant advancements in the identification and application of nucleic acid ligands. His contributions continue to impact the field and hold promise for future developments in disease-targeting technologies.